Medimmune is evaluating takeover offers and has hired Goldman Sachs to help it explore its options. CNBC's David Faber has more on this and an update on Dow Chemical.
Topics:
Biotechnology | Mergers and Acquisitions | Pharmaceuticals
COMMENTS
Thank you for joining our discussion. Your comment has been posted.
Data is a real-time snapshot *Data is delayed at least 15 minutes Market Data Terms of Service
Global Business and Financial News, Stock Quotes, and Market Data and Analysis
More Comments
ADD COMMENTS
PREVIEW COMMENT